Plan-les-Ouates, Geneva, April 2025 – Syrhatech, a French-Swiss CDMO innovating in the
development and manufacture of injectable medical devices based in particular on hyaluronic
acid, announces the closing of an investment of CHF 4.5 million, completed with strategic
investors.
Funding for innovation and industrial capacity.
This investment will enable Syrhatech to strengthen its R&D team at its site in Geneva,
Switzerland, and to deploy a new production capacity at its plant in Chambéry, France, in
order to meet the growing demand of the market for injectable medical devices based on
hyaluronic acid, particularly for aesthetic dermatology but also for orthopedics and
ophthalmology. Other medical specialties should follow.
“This fundraising marks a key milestone for Syrhatech. It allows us to accelerate our
development, strengthen our innovation in hyaluronic acid-based injectable products and
increase our production capacity to support the growth of our partners,” says Gilles Bos, CEO
of Syrhatech.
An opportunity for investors
With this capital increase, Syrhatech offers an exclusive opportunity to investors interested in
a high-potential project in the field of medical devices.
Don’t miss this unique opportunity to participate in our expansion and support innovation in
our sector.
About Syrhatech
Syrhatech is a French-Swiss CDMO specializing in the development and production of
injectable products based on hyaluronic acid and other biopolymers. With 30 years of
experience, the company supports its partners in the R&D, formulation and manufacture of safe and innovative injectable products, primarily marketed as medical devices.
